Trial reportBlood2018
FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.
Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.International journal of molecular sciences · 2024Pooled it
- Development and validation of a gene expression signature to predict early events in patients with follicular lymphoma.Blood advances · 2025Article
- IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma.Blood cancer discovery · 2025Article
- Follicular lymphoma: contemporary clinical management with a focus on recent therapeutic advances.The Korean journal of internal medicine · 2025Review
- Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients.Cancer cell · 2024Article
- Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns.Blood · 2023Article
- Pediatric-type follicular lymphoma: a short review.International journal of hematologic oncology · 2022Review
- Forkhead box protein 1 transcriptionally activates sestrin1 to alleviate oxidized low-density lipoprotein-induced inflammation and lipid accumulation in macrophages.Bioengineered · 2022Article
- FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.Oncogene · 2021Article
- FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness.Journal of cachexia, sarcopenia and muscle · 2021Article
- An Immune-Clinical Prognostic Index (ICPI) for Patients WithFrontiers in oncology · 2021Article
- Good prognosis for follicular lymphoma with estrogen receptor α-positive follicular dendritic cells.Hematological oncology · 2020Article
- MicroRNA-96-5p promotes proliferation, invasion and EMT of oral carcinoma cells by directly targeting FOXF2.Biology open · 2020Article
- Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.Journal of cancer research and clinical oncology · 2020Article
- CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model.Frontiers in oncology · 2020Article
- Novel markers in pediatric-type follicular lymphoma.Virchows Archiv : an international journal of pathology · 2019Article
- Convergence of risk prediction models in follicular lymphoma.Haematologica · 2019Article
- MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.Leukemia · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease, yet prognostication relies predominantly on clinical tools. We recently demonstrated that integration of mutation status of 7 genes, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.